SCHEMBL4432167

SCHEMBL4432167

CCOC(=O)c1ccc2nc(SC)nc(-c3cccc(OC)c3)c2c1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LHCGR P22888 3/20 0.54
TSHR P16473 1/20 0.51
CACNB4 O00305 2/20 0.47
CACNA1A O00555 2/20 0.47
CACNA1G O43497 2/20 0.47
CACNG3 O60359 2/20 0.47
CACNA1F O60840 2/20 0.47
CACNA1H O95180 2/20 0.47
CACNB3 P54284 2/20 0.47
CACNA2D1 P54289 2/20 0.47
CACNG7 P62955 2/20 0.47
CACNA1B Q00975 2/20 0.47
CACNA1D Q01668 2/20 0.47
CACNB1 Q02641 2/20 0.47
CACNG1 Q06432 2/20 0.47
CACNB2 Q08289 2/20 0.47
CACNA1S Q13698 2/20 0.47
CACNA1C Q13936 2/20 0.47
CACNA1E Q15878 2/20 0.47
CACNA2D4 Q7Z3S7 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143226 0.96 LHCGR (0.51) LHCGRTSHRCACNB4CACNA1ACACNA1G
SCHEMBL4423867 0.90 LHCGR (0.48) LHCGRTSHRCSNK1DALDH1A1KDM4E
SCHEMBL4421572 0.89 SMN1; SMN2 (0.50) LHCGRTSHRCSNK1DALDH1A1KDM4E
SCHEMBL4418728 0.87 LHCGR (0.57) LHCGRTSHRKDM4EMAPT
SCHEMBL4423898 0.87 LHCGR (0.55) LHCGRTSHRKDM4EHSD17B10MAPT
SCHEMBL4421035 0.84 ACHE (0.49) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL4423875 0.82 LHCGR (0.69) LHCGRTSHRMAPT
SCHEMBL4327613 0.81 LHCGR (0.77) LHCGRTSHRALDH1A1KDM4EHPGD
SCHEMBL4428948 0.79 LHCGR (0.52) LHCGRTSHRKDM4EMAPTLMNA
SCHEMBL4430395 0.78 LHCGR (0.51) LHCGRTSHRALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618963-B2 Bicyclic heteroaromatic compounds N.V. ORGANON (NL) 2009-11-17 US disclosed
EP-1886999-A2 Bicyclic heteroaromatic compound N.V. Organon (NL) 2008-02-13 EP disclosed
US-20070197527-A1 Bicyclic heteroaromatic compounds N.V. ORGANON (NL) 2007-08-23 US disclosed
US-7229990-B2 Bicyclic heteroaromatic compounds N.V. ORGANON (NL) 2007-06-12 US disclosed
CN-1247594-C Bicyclic heteroaromatic compounds OKZO NOBEL N V (NL) 2006-03-29 CN disclosed
CN-1462273-A Bicyclic heteroaromatic compounds OKZO NOBEL N V (NL) 2003-12-17 CN disclosed
US-20030225113-A1 Bicyclic heteroaromatic compounds MERCK SHARP & DOHME B.V. (NL) 2003-12-04 US disclosed
EP-1322651-A1 BICYCLIC HETEROAROMATIC COMPOUNDS Akzo Nobel N.V. (NL) 2003-07-02 EP disclosed
WO-2002024703-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AKZO NOBEL N.V. (NL) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225113-A1 Bicyclic heteroaromatic compounds NR5A1, CYP19A1, FSHR LHCGR 13/4885TSHR 1000/4885CACNB4 811/4885
US-20070197527-A1 Bicyclic heteroaromatic compounds NR5A1, CYP19A1, FSHR LHCGR 10/4885TSHR 517/4885CACNB4 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.